Enanta Pharmaceuticals logo

Enanta Pharmaceuticals (ENTA) Q1 2026 Earnings

ENTA·Reported May 11, 2026·Before market open

Enanta Pharmaceuticals reported Q1 2026 revenue of $17.2M (+15.0% YoY), beat analyst consensus of $17.0M by $131.7K. Diluted EPS came in at $-0.45 (+57.5% YoY), beat the $-0.46 consensus by $0.01.

Revenue
$17.2Mbeat by $131.7K
Consensus: $17.0M
Diluted EPS
$-0.45beat by $0.01
Consensus: $-0.46
SEC

SEC Filings

Earnings release8-K · 0001193125-26-216735
Quarterly report10-Q · 0001193125-26-220572

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Enanta Pharmaceuticals's Q1 2026 earnings report.

Enanta Pharmaceuticals (ENTA) reported Q1 2026 earnings on May 11, 2026 before market open.

Enanta Pharmaceuticals reported revenue of $17.2M and diluted EPS of $-0.45 for Q1 2026.

Revenue beat the consensus estimate of $17.0M by $131.7K. EPS beat the consensus estimate of $-0.46 by $0.01.

Compared to the same quarter a year prior, revenue grew 15.0% from $14.9M a year earlier and diluted EPS grew 57.5% from $-1.06.

You can read the 8-K earnings release (0001193125-26-216735) and the 10-Q periodic report (0001193125-26-220572) directly on SEC EDGAR. The filing index links above go to sec.gov.